TIMELINE MAJOR ADVANCES
The vast majority of biotechnology advancements evolve from years of research, either within a University or the research arm of a major biopharmaceutical company, and as such, are provided with substantial budgets for the entire development process.
ProteoNova began as simply an idea. Without University or biopharma backing, ProteoNova called in favors, took on investors, and was able to continue the research. Despite what at times seemed like insurmountable odds, the company has managed to successfully develop the AcPET system. The following historical timeline presents the key events in the development of our technology.
2000: COMPANY FORMED
In the fall of 2000, over a coffee shop table, the development of an idea was put into motion. There was no major funding, no laboratory to use for development, only the determination of a few individuals to pursue an idea that could revolutionize the development of new drug treatments for virtually any disease.
Company incorporated, initially called proGenesys.
Received first investment dollars in December 2000.
Company incorporated, initially called proGenesys.
Received first investment dollars in December 2000.
2001: INITIAL CONTRACT
Calling in favors from past colleagues, the research began in early 2001 at the Illinois Institute of Technology. The research continued there for almost a year under the direction of Dr. Williams and Dr. Guerrero.
Retained Knobbe Martens Olson & Bear as intellectual property legal firm.
In late 2001 the name was officially changed to ProteoNova due to conflicts in filing patent documents using the original name.
November 2001 the research moved to University of Southern California, Clinical Reference Laboratory (USCCRL) under a contract basis. A full time researcher, Juren Huang, Ph.D., was hired by ProteoNova to work at USCCRL on the project.
Retained Knobbe Martens Olson & Bear as intellectual property legal firm.
In late 2001 the name was officially changed to ProteoNova due to conflicts in filing patent documents using the original name.
November 2001 the research moved to University of Southern California, Clinical Reference Laboratory (USCCRL) under a contract basis. A full time researcher, Juren Huang, Ph.D., was hired by ProteoNova to work at USCCRL on the project.
2008: R&D MOVED TO AMERICAN INTERNATIONAL BIOTECHNOLGY SERVICES (AIBT)
Beginning 2008, entered into contract with AIBT to continue research at full-time pace.
Late 2008, first DNA library synthesized at AIBT. The reagents were developed at Integrated DNA Technology (IDT) utilizing new equipment developed by IDT specifically to work on our project. All under contract.
Late 2008, first DNA library synthesized at AIBT. The reagents were developed at Integrated DNA Technology (IDT) utilizing new equipment developed by IDT specifically to work on our project. All under contract.
2013: NEWPORT SCIENTIFIC
The work was moved to Newport Scientific Inc. for final development of our proprietary UV light cross linking system. Utilizing our proprietary cross linker reagent synthesized at TriLink Biotchnologies, the photochemist at Newport also developed our first cross linking protocol.
2015: ALL R&D MOVED TO NEW LAB
Early in 2015, with the UV light system developed, all R&D was moved to the west coast at Marin Biologic.
2017: 1st SUCCESSFUL mRNA-LINKER-PROTEIN COMPLEX FORMED
In late 2107, the mRNA-linker-protein complex was successfully formed.
2018: MOVED TO NEW LAB
Moved to LakePharma Inc to expand on the successful complex formation by developing the methodology for mass production and better yield of the complex, and also to develop its first commercial product, a bifunctional protein cancer therapeutic.
2019: MONETIZATION
Projected: commercialization such as licensing and partnering with big pharma